Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show that CYC065 (fadraciclib), a clinical inhibitor of CDK9 and CDK2, selectively ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Poon, Evon, Liang, Tong, Jamin, Yann, Walz, Susanne, Kwok, Colin, Hakkert, Anne, Barker, Karen, Urban, Zuzanna, Thway, Khin, Zeid, Rhamy, Hallsworth, Albert, Box, Gary, Ebus, Marli E., Licciardello, Marco P., Sbirkov, Yordan, Lazaro, Glori, Calton, Elizabeth, Costa, Barbara M., Valenti, Melanie, De Haven Brandon, Alexis, Webber, Hannah, Tardif, Nicolas, Almeida, Gilberto S., Christova, Rossitza, Boysen, Gunther, Richards, Mark W., Barone, Giuseppe, Ford, Anthony, Bayliss, Richard, Clarke, Paul A., De Bono, Johann, Gray, Nathanael S., Blagg, Julian, Robinson, Simon P., Eccles, Suzanne A., Zheleva, Daniella, Bradner, James E., Molenaar, Jan, Vivanco, Igor, Eilers, Martin, Workman, Paul, Lin, Charles Y., Chesler, Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598076/
https://www.ncbi.nlm.nih.gov/pubmed/33016930
http://dx.doi.org/10.1172/JCI134132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598076/
https://www.ncbi.nlm.nih.gov/pubmed/33016930
http://dx.doi.org/10.1172/JCI134132

Ejemplares similares